Delivery Order SPE2DB25D9348-SPE2DB25FNMWT
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,999.80 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Jakafi 15 mg tablets (60-count units). This firm fixed-price delivery order, issued on September 5, 2025, with an ultimate completion date of September 8, 2025, carries no set-aside designation. The award falls under DMS Pharmaceutical Group's existing Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Jakafi 10 mg tablets (60-count units). This firm fixed-price delivery order, valued at $12,115.65, was awarded on July 22, 2025, with an ultimate completion date of July 23, 2025. The award carries no set-aside designation and represents a single delivery order issued under DMS Pharmaceutical Group's larger...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $12,146.79 by the Defense Logistics Agency (DLA) on September 2, 2025, for the supply of Jakafi 5 mg tablets (60-count units). The contract represents a firm fixed-price delivery order with an ultimate completion date of September 3, 2025, and was awarded without set-aside designation. This delivery order is issued under DMS Pharmaceutical...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order by the Defense Logistics Agency (DLA) on August 27, 2025, for the supply of Jakafi 15 mg tablets (60-count units). This firm fixed-price delivery order, valued at $36,115.27, represents a single issuance under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA under the SPE2DB program, which carries a total value of $500...
- The Defense Logistics Agency awarded a delivery order valued at $16,285.24 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Jakafi 10 mg tablets (60-count units). This firm fixed-price delivery order, awarded on September 8, 2025, with an ultimate completion date of September 9, 2025, was issued without a set-aside designation. The contract is executed under DMS Pharmaceutical Group's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $48,462.60 to DMS Pharmaceutical Group Inc. for the supply of Jakafi 10 mg tablets (60-count units) on September 16, 2025, with an ultimate completion date of September 17, 2025. This firm fixed-price delivery order was issued without a set-aside designation to the Park Ridge, Illinois-based woman-owned small business pharmaceutical wholesaler. The award represents a continuation of DMS Pharmaceutical Group's established role as a...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $86,098.80 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, on September 17, 2025. The delivery order is for Jakafi 15 mg tablets (60-count units) under a firm fixed-price contract type with an ultimate completion date of September 18, 2025. This award carries no set-aside designation and represents a direct delivery order issued against DMS...
- The Defense Logistics Agency awarded a delivery order valued at $24,293.60 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Jakafi 5 mg tablets (60-count units). This firm fixed-price delivery order was awarded on July 18, 2025, with an ultimate completion date of July 21, 2025, and carries no set-aside designation. The award falls under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Jakafi 20 mg tablets (60-count). The contract is valued at approximately $24.2K with a firm fixed-price structure and an ultimate completion date of September 17, 2025. This delivery order was issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA valued at $500M through...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order on September 2, 2025, for Jakafi 10 mg tablets (60-count units) valued at $12,915.65. This firm fixed-price delivery order was issued by the Defense Logistics Agency (DLA), a component of the Department of Defense, with an ultimate completion date of September 3, 2025. The contract carries no set-aside designation, allowing DMS Pharmaceutical Group...
- SPE2DB25D9348Indefinite Delivery Contract
- SPE2DB25D9348-SPE2DB25FNMWTDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $48,524.90 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Jakafi 5 mg tablets (quantity: 60s). The contract is firm fixed-price with no set-aside designation and an ultimate completion date of September 5, 2025. This delivery order is issued under DMS Pharmaceutical Group's existing single-award Indefinite Delivery Contract with the DLA under the SPE2DB program, which carries a total contract value of $499,999,999 and extends through November 2026. DMS Pharmaceutical Group serves as a critical supplier within the federal pharmaceutical supply chain, distributing a comprehensive range of branded and generic prescription drugs, biologics, and medical consumables to Department of Defense healthcare facilities nationwide. The company has maintained consistent contract awards with the DLA since its SAM.gov registration in 2001, leveraging its woman-owned small business status to compete effectively in federal procurement markets. Jakafi (ruxolitinib) is a prescription medication used primarily in the treatment of myelofibrosis and other hematologic conditions, supporting the medical supply needs of military health facilities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $48.5k | 9/4/25 |